许多研究人员同意多模式疗法通常是间皮瘤患者最成功的治疗方法。万博专业版但是，组合的功效mesothelioma treatmentsvaries on a case-by-case basis.
临床试验通常着重于提高间皮瘤患者的治疗效果和存活率。万博专业版一项这样的试验设置为测试两种免疫疗法药物作为治疗前的手术选择pleural mesothelioma patients。这是在手术前首次测试间皮瘤的免疫疗法。万博专业版
Using Immunotherapy Drugs Before Surgery
免疫疗法对于间皮万博专业版瘤治疗是新兴治疗选择。The therapy helps the immune system kill cancer cells.
Many万博专业版间皮瘤研究人员已经研究了免疫疗法。但是，专家从未测试过免疫疗法药物作为该特定癌症的预处理。
拟议的临床试验将test two different immunotherapy treatment regimens。
研究人员将对恶性胸膜间皮瘤患者进行两种方案。万博专业版这些患者尚未接受过任何对癌症的治疗。预处理后，患者将有surgery。
完成临床试验方案（免疫疗法和手术）后，患者可以接受任何适合其特定病例的治疗方法。
重要的临床试验统计
临床试验具有不同的资格标准。因此，每项试验可能并不适合所有间皮瘤患者。万博专业版该特殊的临床试验对大部分胸皮间皮瘤患者开放。万博专业版
The clinical trial is:
- accepting 30 patients.
- 预期运行到2026年。
- 运行Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins。
这些药物是什么？
Nivolumab和ipilimumab是两种免疫疗法药物。这些免疫疗法涵盖或隐藏了特定的蛋白质。通过隐藏特定的蛋白质，这些药物对患者免疫系统产生了期望的反应。
这些免疫疗法以前是否在间皮瘤中使用过？万博专业版
These two immunotherapy drugs (nivolumab and ipilimumab) have been used for mesothelioma treatment. However, the drugs have not been used neoadjuvantly before this clinical trial.
Two earlier studies investigated the drugs in patients. Prior to treatment, these patients were treated with at least one round ofchemotherapy。两项研究中使用的化学疗法均为刺激/铂联合疗法。
研究中患者的中位生存期如下。
| Median Survival Times of Patients Treated With Nivolumab Or Nivolumab + Ipilimumab | ||
|---|---|---|
| Nivolumab | Nivolumab + Ipilimumab | |
| MAPS-2研究 | 11.9个月 | 15.9个月 |
| 启动研究 | Not Tested | > 12.7个月 |
The results from these studies may act as a guide for patients of possible results. However, patients should discuss expectations for their specific case with their medical team.
临床试验是否有潜在的风险？
There have not been any results reported about this trial. However, side effects may be similar to those reported in other trials using the same immunotherapy drugs.
在以前的研究中，几个患者的频率较低pleural effusion治疗后。当有肺液积聚时，就会产生积液。根据液体积聚的严重程度，患者可能需要缓解症状的程序。
While rare, all clinical trials have risks. For example, three patients died in the combination therapy group of one previous study. The MAPS-2 researchers attributed the deaths to mismanagement of treatment complications. All three patient deaths were in the first months of the study.
另一项类似的研究没有任何患者死亡。
Who Is Eligible for the Trial?
这种临床试验的资格要求re not strict to allow more patients to take part in the opportunity. The researchers offer flexibility in:
- 谁有资格参加审判
- 治疗s available to patients once the trial has ended
一旦入学并完成，试验参与者就不会受到未来治疗的限制。患者可以寻求最适合其个人情况的进一步治疗。
The goal of immunotherapy before surgery is to increase patient survival. However, adding other treatments after the clinical trial may further improve patient outcomes.
